FEDERAL CIRCUIT OKS GENERIC VERSION OF EAGLE PHARMA CHEMOTHERAPY DRUG

摘要

Generic drug company Slayback Pharma LLC on May 8 won an appeals court decision that clears the way for it to launch a generic version of the Eagle Pharmaceuticals Inc. chemotherapy drug Belrapzo. The U.S. Court of Appeals for the Federal Circuit affirmed a ruling that Slayback's proposed generic does not infringe four related Eagle patents on the medicine, saying a Delaware judge properly decided infringement during the early pleadings stage of the case. The ruling was a win for Constance Huttner of Windels Marx Lane & Mittendorf, who argued against Eagle's appellate counsel Daniel Brown of Latham & Watkins.